Mesoblast Limited
Level 1, 843A Glenhuntly Road
Caulfield South
VIC
3162
Tel: 03-9618-7000
263 articles with Mesoblast Limited
-
Just as 2021 was wrapping up, the U.S. FDA had some end-of-year activity. Here’s a look.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
FDA’s OTAT in Agreement With 12-Month Reduction in Pain as Primary Endpoint for Chronic Low Back Pain Program
12/16/2021
Mesoblast Limited announced that it has received feedback from the US Food & Drug Administration’s Office of Tissues and Advanced Therapies on the Phase 3 program of rexlemestrocel-L in patients with chronic low back pain due to degenerative disc disease refractory to available therapies, including opioids.
-
Update on Novartis Agreement - Dec 14, 2021
12/14/2021
Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, was notified by Novartis that it has chosen to terminate the agreement with Mesoblast prior to closing.
-
Novartis has grown weary of waiting, dropping out of its deal to fund Mesoblast’s floundering COVID-19 treatment.
-
Clinical Catch-Up: December 6-10
12/13/2021
There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look. -
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
The latest updates from Mesoblast Limited's Phase III trial on rexlemestrocel-L show that the drug provides the highest benefit when used in patients with certain types of chronic heart failure.
-
Rexlemestrocel-L Shows Greatest Treatment Benefit on Major Adverse Cardiovascular Events in High-Risk Heart Failure Patients With Diabetes and/or Myocardial Ischemia
12/5/2021
Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, provided new analyses from the landmark DREAM-HF Phase 3 trial showing that the greatest treatment benefit from rexlemestrocel-L is in HFrEF patients with diabetes and/or ischemia, who are at high-risk of cardiovascular mortality, heart attacks or strokes.
-
Operational Highlights and Financial Results for the Period Ended September 30, 2021
11/23/2021
Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, reported operational highlights and financial results for the first quarter ended September 30, 2021.
-
Mesoblast and Oaktree Capital Enter Into Refinancing and Expansion of Senior Debt Facility
11/22/2021
Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, announced that it has successfully refinanced its existing senior debt facility with a new US$90 million five year facility provided by funds managed by Oaktree Capital Management, L.P..
-
Clinical Catch-Up: November 15-19
11/22/2021
With the last full week before the Thanksgiving week in the U.S., companies had a fair amount of clinical trial news. Here’s a look. -
Three companies have posted major developments in the field of heart disease therapy.
-
Late Breaking Presentation at American Heart Association Annual Meeting of Landmark Phase 3 Trial of Rexlemestrocel-L in Chronic Heart Failure
11/15/2021
Mesoblast Limited announced that results from the randomized, controlled Phase 3 trial of rexlemestrocel-L in 565 patients with New York Heart Association class II and class III chronic heart failure with reduced ejection fraction were presented as a late breaking presentation at the American Heart Association annual Scientific Sessions during a featured program titled ‘Building on the Foundations of Treatment: Advances in Heart Failure Therapy’.
-
Appendix 4C Quarterly Activity Report - Oct 28, 2021
10/28/2021
Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, provided an activity report for the first quarter ended September 30, 2021, and an update on its pipeline of late-stage product candidates.
-
Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations.
-
Mesoblast shares dropped on the last day of August 2021 after it was told that its candidate COVID-19 treatment needs to undergo another trial to be green-lit for emergency approval by the FDA.
-
Appendix 4C Quarterly Activity Report
7/30/2021
Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, provided an update on its pipeline of late-stage product candidates, and an activity report for the fourth quarter ended June 30, 2021.
-
Clinical Catch-Up: July 19-23
7/26/2021
It was another busy week for clinical trial updates. Here’s a look at some including Mesoblast Limited, CytoDyn, Magenta Therapeutics and more. -
Ninety Day Survival Outcomes in COVID-19 ARDS Trial of Remestemcel-L Presented at ISCT Meeting on Advances in Cell & Gene Therapies for Lung Diseases
7/19/2021
Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, presented 90-day survival outcomes from the 222-patient randomized controlled trial of remestemcel-L in ventilator-dependent COVID-19 patients with moderate/severe acute respiratory distress syndrome at an invited presentation on July 17 to the International Society for Cell & Gene Therapy Scientific Signatures Series on Cell and Gene Therapies in Lung Diseases and Critical Illnesses.